Data from key studies highlight the value of individualized therapy and reinforce Lucentis (ranibizumab) well-characterized long-term efficacy and safety profile - RESTORE extension study in DME patients shows mean of 3.7 and 2.7 Lucentis

Kidney tumors affect up to 80% of patients with tuberous sclerosis complex (TSC) and growing tumors may lead to unpredictable life-threatening complications - Prior to the approval of Afinitor, surgical intervention was the only treatment o

Sandoz faced a strong year-ago base with enoxaparin exclusivity and Consumer Health impacted by the suspension of production at the Lincoln, Nebraska manufacturing site - Core operating income of USD 3.7 billion (-6% cc) driven by Sandoz and Co

Updated Gilenya label provides further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients in the United States - Prescribing information includes patient selection parameters to aid in the identific

Combination product Valturna to be voluntarily withdrawn from the US market as of July 20, 2012 - Basel, Switzerland April 19, 2012 - Novartis announced today that the Tekturna labels have been updated in the US, following the US Food and Drug Administration's (FDA) review of the preliminary findings from the ALTITUDE study.

Collaboration with the Broad Institute yields comprehensive encyclopedia of genetic and molecular information for nearly 1,000 cancer cell lines - Basel, March 28, 2012 - Novartis and the Broad Institute have developed a cancer cell line encyclopedia that catalogues the genetic and molecular profiles of almost 1,000 human cancer cell lines used in drug research and development.

Study met primary endpoint showing Signifor (pasireotide) normalized cortisol overproduction , a critical factor in controlling the debilitating endocrine disorder , , - Cortisol levels decreased quickly in the majority of patients and

Patients on pasireotide (SOM230) LAR were 63% more likely to achieve full biochemical control than those on Sandostatin LAR, the current standard of care - Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in

Signifor is first targeted approach for Cushing's disease, a debilitating endocrine disorder caused by an underlying pituitary tumor that triggers excess cortisol , , - Majority of patients in the Phase III clinical trial experienced a rap

Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer - Patients with myelofibrosis experience severe symptoms due to overactive signa

Revised label agreed between Novartis and the CHMP provides further guidance to healthcare providers regarding treatment initiation with Gilenya in MS patients in the EU - Patients should have ECG before and six hours after the first-dose, w

QVA149, a bronchodilator with dual mode of action, is Novartis' third innovation in its Breezhaler Single Dose Dry Powder Inhaler - COPD is predicted to be the third leading cause of death in the world by 2020 - Basel, April

Symptomatic vitreomacular adhesion (VMA) is a progressive, debilitating eye disease, there is currently no pharmacological treatment available - Phase III clinical data demonstrate resolution of symptomatic VMA following

Approval based on Phase III study showing significant recurrence-free and overall survival after three years of adjuvant Glivec in adults with KIT+ GIST - Adults with KIT+ GIST are at risk of recurrence following surgical removal of the p